机器人辅助与传统二尖瓣修复的临床结局与费用:全国性分析
基于美国全国再入院数据库2016至2020年择期二尖瓣修复成人患者,比较机器人辅助与传统手术的短期结局与费用。机器人辅助组死亡率、卒中、再手术、呼吸并发症、感染和再入院风险调整后相当,非家庭出院率更低;总体费用更高,但高手术量中心两种术式风险调整后费用相近。
要点
- 机器人辅助二尖瓣修复短期结局与传统手术相当,非家庭出院率更低。
- 总体机器人辅助费用更高,风险调整后多10500美元,但住院时间缩短1.3天。
- 高手术量中心两种术式风险调整后费用相近,支持在卓越中心开展机器人二尖瓣修复。
核心结论
- 机器人辅助二尖瓣修复短期结局与传统手术相当,总体费用更高,但高手术量中心费用相近。
研究设计与样本
- 回顾性队列研究,使用美国全国再入院数据库2016至2020年择期二尖瓣修复成人患者,排除风湿性心脏病、二尖瓣狭窄及同期手术者。
主要发现
- 共40738例患者,9.8%接受机器人辅助二尖瓣修复。
- 机器人辅助组非家庭出院率更低,其余风险调整结局 including 死亡率、卒中、再手术、呼吸并发症、感染和再入院均相当。
- 机器人辅助二尖瓣修复中位费用为46800美元,传统手术为38500美元(P < .001)。
- 机器人辅助二尖瓣修复住院时间缩短1.3天(95% CI, 1.1-1.6),但风险调整后费用高10500美元(95% CI, 5800-15200)。
- 最高手术量三分位中心两种术式费用差异为5900美元(95% CI, -1200至12200;P > .05)。
临床怎么用
- 机器人辅助二尖瓣修复可在高手术量卓越中心开展,以平衡费用与结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robotic approaches have been increasingly utilized for cardiothoracic operations, though concerns regarding costs remain. We evaluated short-term outcomes and costs of robotic-assisted and conventional mitral valve repair (MV-repair), hypothesizing that cost differences would be mitigated at high-volume programs. METHODS: Adults undergoing elective MV-repair from 2016 to 2020 were identified in the Nationwide Readmissions Database. Patients with rheumatic heart disease, mitral stenosis, and those undergoing concomitant operations were excluded. Generalized linear models were utilized to evaluate the association between approach and in-hospital mortality, complications, length of stay, costs, and 90-day readmissions. Annual institutional MV-repair volume was modeled using restricted cubic splines, and cost differences subsequently evaluated by volume tertile. RESULTS: Of 40,738 patients, 9.8% underwent robotic-assisted MV-repair. Risk-adjusted outcomes including mortality, stroke, reoperation, respiratory complications, postoperative infection, and readmission were comparable between the 2 groups, while those undergoing robotic-assisted MV-repair had lower rates of nonhome discharge. The median cost of robotic-assisted MV-repair was greater than conventional surgery ($46,800 vs $38,500, P < .001). Despite a 1.3-day decrement (95% CI, 1.1-1.6) in length of stay, robotic-assisted MV-repair was associated with greater risk-adjusted costs by $10,500 (95% CI, $5800-$15,200). Programs in the highest volume tertile exhibited comparable costs for robotic-assisted and conventional MV-repair (cost difference, $5900; 95% CI, -$1200 to $12,200; P > .05). CONCLUSIONS: Robotic-assisted MV-repair had comparable short-term outcomes relative to conventional surgery. Despite increased costs of robotic-assisted MV-repair overall, high-volume programs had similar risk-adjusted costs by approach. These findings support the designation and performance of robotic MV-repair at centers of excellence in the United States.
引用
- Hadaya J, Chervu NL, Ebrahimian S, et al. Clinical Outcomes and Costs of Robotic-assisted vs Conventional Mitral Valve Repair: A National Analysis. Ann Thorac Surg. 2024. PMID: 39536852. doi:10.1016/j.athoracsur.2024.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。